Literature DB >> 18195057

Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts.

Manuel Cuenca-Estrella1, Alicia Gomez-Lopez, M Olga Gutierrez, M Jose Buitrago, Juan L Rodriguez-Tudela.   

Abstract

This study evaluated the WIDERYST system, a commercially available computer-assisted image-processing device for the antifungal susceptibility testing of yeasts. A collection of 90 clinical isolates selected to represent ranges of susceptibilities in vitro as broad as possible was tested. An evaluation compared the results obtained by the new system with those achieved by both the Clinical and Laboratory Standards Institute (CLSI) microdilution reference procedure and the antifungal susceptibility standard of the European Committee for Antimicrobial Susceptibility Testing (EUCAST). Overall, the agreement and the correlation index between results obtained by the EUCAST method and the WIDERYST system were 89% and 0.84 (P < 0.01), respectively, and agreement and correlation index between data obtained by the CLSI procedure and the WIDERYST system were 90% and 0.86 (P < 0.01), respectively. The system was able to detect amphotericin B-resistant isolates. All Candida sp. isolates with resistance in vitro to azole agents were detected as well. The system misclassified some isolates belonging to the slowly growing genera Dipodascus and Pichia. A total of 2.7% very major errors were detected for fluconazole. The WIDERYST system is an alternative to reference procedures for antifungal susceptibility testing of clinical isolates of yeasts, particularly for Candida and Cryptococcus species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195057      PMCID: PMC2258493          DOI: 10.1128/AAC.01016-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing.

Authors:  R Cantón; M Pérez-Vázquez; A Oliver; B Sánchez Del Saz; M O Gutiérrez; M Martínez-Ferrer; F Baquero
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Standardization of antifungal susceptibility variables for a semiautomated methodology.

Authors:  J L Rodríguez-Tudela; M Cuenca-Estrella; T M Díaz-Guerra; E Mellado
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

3.  Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.

Authors:  Manuel Cuenca-Estrella; Wendy Lee-Yang; Meral A Ciblak; Beth A Arthington-Skaggs; Emilia Mellado; David W Warnock; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose.

Authors:  J L Rodríguez-Tudela; F Martín-Díez; M Cuenca-Estrella; L Rodero; Y Carpintero; B Gorgojo
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

5.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

7.  In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

8.  Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques.

Authors:  M Cuenca-Estrella; A Gomez-Lopez; E Mellado; J L Rodriguez-Tudela
Journal:  Clin Microbiol Infect       Date:  2005-06       Impact factor: 8.067

9.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

10.  Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Authors:  M Cuenca-Estrella; C B Moore; F Barchiesi; J Bille; E Chryssanthou; D W Denning; J P Donnelly; F Dromer; B Dupont; J H Rex; M D Richardson; B Sancak; P E Verweij; J L Rodríguez-Tudela
Journal:  Clin Microbiol Infect       Date:  2003-06       Impact factor: 8.067

View more
  1 in total

1.  Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.

Authors:  Brunella Posteraro; Rosa Martucci; Marilena La Sorda; Barbara Fiori; Dominique Sanglard; Elena De Carolis; Ada Rita Florio; Giovanni Fadda; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.